Age Patterns Across 13,368 Spanish Patch-Test Patients

November 11, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

Reader question: What can this study tell workers, families and occupational-health teams—and what would go beyond the evidence? This review keeps every number attached to its population, denominator, comparator and timepoint.

Study snapshot

Study element	Reported detail
Population	13,368 patients patch tested with the Spanish baseline series at participating centers from 2019 through 2023.
Design	Prospective multicenter clinical surveillance study with predefined age groups and multivariable logistic regression.
Comparator	Children, adolescents, young adults, middle-aged adults and older adults; young adults were the regression reference group.
Timepoint	Patch-test encounters collected during 2019–2023.
Key result	Compared with young adults, positive results were more frequent in adults aged 31–65 years (adjusted OR 1.41, 95% CI 1.26–1.58) and those 66 or older (adjusted OR 1.15, 95% CI 1.01–1.32). Most tested haptens did not show age-related differences.
Funding/conflict context	The PubMed grant list names the Spanish Academy of Dermatology and Venereology, the Spanish Medicines and Health Products Agency and Sanofi; the retrieved record has no separate conflict statement.

What was actually measured?

Compared with young adults, positive results were more frequent in adults aged 31–65 years (adjusted OR 1.41, 95% CI 1.26–1.58) and those 66 or older (adjusted OR 1.15, 95% CI 1.01–1.32). Most tested haptens did not show age-related differences.

The large multicenter sample and adjustment for sex, atopic dermatitis, body site and occupational dermatitis strengthen the age comparison. The result still describes people referred for patch testing, not the general population.

The denominator defines the scope. A patch-test clinic, selected case series, compensation registry, online questionnaire, workplace cohort and general-population survey answer different questions. A percentage from one cannot be silently transferred to the others.

What the result does not prove

Referral thresholds, center mix and exposure histories may differ by age. Odds ratios describe association, and a positive patch test does not by itself establish clinical relevance or workplace causation.

Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting practices, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors' conclusions, this interpretation or any product.

Exposure detail matters more than the job label

Workers with the same title can handle different materials for different durations. Useful documentation identifies the exact product or process, the route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.

A symptom survey can identify a pattern, a clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None of those steps alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.

Questions worth recording

Which task, product, glove, tool, metal, resin, cleanser, food, plant, dust or surface came before symptoms?
Where did the change begin, and did it improve on days away or after a process or PPE change?
How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
Were labels, ingredient information and safety-data sheets reviewed with occupational health?
Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?

Prevention comes before cosmetic care

Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.

Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.

Primary research and guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.

← Back to Doctor's Notes